C
Cheng Zhang
Researcher at Third Military Medical University
Publications - 45
Citations - 1258
Cheng Zhang is an academic researcher from Third Military Medical University. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Leukemia. The author has an hindex of 13, co-authored 43 publications receiving 691 citations. Previous affiliations of Cheng Zhang include University of Southern California & Temple University.
Papers
More filters
Journal ArticleDOI
Engineering CAR-T cells.
TL;DR: The structure and evolution of chimeric antigen receptors are discussed, and the tools used for production of CAR-T cells are reported on, to address the challenges posed by the technology.
Journal ArticleDOI
Recent advances in CAR-T cell engineering
Ruihao Huang,Xiaoping Li,Yundi He,Wen Zhu,Lei Gao,Yao Liu,Li Gao,Qin Wen,Jiang F. Zhong,Cheng Zhang,Xi Zhang +10 more
TL;DR: The recent transformations in the ectodomain, transmembrane domain, and endodomains of the CAR structure are summarized, which, together with innovative manufacturing technology and improved cell sources, improve the prospects for the future development of CAR-T cell therapy.
Journal ArticleDOI
Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord–Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation
Lei Gao,Yanqi Zhang,Baoyang Hu,Jia Liu,Peiyan Kong,Shifeng Lou,Yi Su,Tonghua Yang,Huimin Li,Yao Liu,Cheng Zhang,Li Gao,Li-dan Zhu,Qin Wen,Ping Wang,Xinghua Chen,Jiangfan Zhong,Xi Zhang +17 more
TL;DR: The findings suggest that the repeated infusion of MSCs might inhibit cGVHD symptoms in patients after HLA-haplo HSCT, accompanied by changes in the numbers and subtypes of T, B, and NK cells, leading to the acquisition of immune tolerance.
Journal ArticleDOI
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
TL;DR: The treatment of allogeneic CAR-T cells is beneficial for patients with relapsed B cell malignancies after allo-HSCT with low toxicities and complications, however, multicenter clinical trials with larger sample sizes should be performed to select the optimal therapeutic window and confirm its efficacy.
Journal ArticleDOI
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
Lei Gao,Yanqi Zhang,Sanbin Wang,Pei-Yan Kong,Yi Su,Jiong Hu,Ming Jiang,Hai Bai,Tao Lang,Jishi Wang,Li Liu,Tonghua Yang,Xiaobing Huang,Fang Liu,Shifeng Lou,Yao Liu,Cheng Zhang,Hong Liu,Li Gao,Jia Liu,Lidan Zhu,Qin Wen,Ting Chen,Ping Wang,Jun Rao,Min Mao,Cunbang Wang,Xianlin Duan,Le Luo,Xian-Gui Peng,Kaniel Cassady,Jiang F. Zhong,Xi Zhang +32 more
TL;DR: It is suggested that rhG-CSF combined with minimal-dose Dec maintenance after allo-HSCT can reduce the incidence of relapse, accompanied by changes in the number of lymphocyte subtypes.